Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
92.06 USD | +2.87% | +1.31% | -4.52% |
Financials (USD)
Sales 2024 * | 2.76B | Sales 2025 * | 3.14B | Capitalization | 17.47B |
---|---|---|---|---|---|
Net income 2024 * | 306M | Net income 2025 * | 484M | EV / Sales 2024 * | 6.01 x |
Net cash position 2024 * | 883M | Net cash position 2025 * | 1.36B | EV / Sales 2025 * | 5.14 x |
P/E ratio 2024 * |
57.9
x | P/E ratio 2025 * |
35.8
x | Employees | 3,401 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.16% |
Latest transcript on BioMarin Pharmaceutical Inc.
1 day | +2.87% | ||
1 week | +1.31% | ||
Current month | +5.40% | ||
1 month | +8.14% | ||
3 months | -1.05% | ||
6 months | +11.13% | ||
Current year | -4.52% |
Managers | Title | Age | Since |
---|---|---|---|
Alexander Hardy
CEO | Chief Executive Officer | 56 | Nov. 30 |
Brian Mueller
DFI | Director of Finance/CFO | 50 | 02-11-30 |
Kevin Eggan
CTO | Chief Tech/Sci/R&D Officer | - | 20-10-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Pyott
BRD | Director/Board Member | 70 | 16-01-03 |
Director/Board Member | 70 | 05-05-15 | |
Randy Meier
CHM | Chairman | 65 | 06-12-13 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.45% | 1 M€ | 0.00% | - | |
1.79% | 0 M€ | 0.00% | - | |
1.59% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-23 | 92.06 | +2.87% | 1,299,078 |
24-04-22 | 89.49 | +0.97% | 1,257,361 |
24-04-19 | 88.63 | -1.60% | 1,778,647 |
24-04-18 | 90.07 | -0.44% | 944,850 |
24-04-17 | 90.47 | -0.44% | 1,282,481 |
Delayed Quote Nasdaq, April 23, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.52% | 17.47B | |
-2.76% | 87.37B | |
+4.08% | 41.01B | |
-25.35% | 28.08B | |
+54.31% | 24.72B | |
-42.09% | 11.69B | |
-17.77% | 11.6B | |
-12.10% | 11.56B | |
+0.75% | 8.44B | |
+3.32% | 7.72B |
- Stock Market
- Equities
- BMRN Stock